PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2116465
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2116465
According to Mordor Intelligence, the medical tubing market size was valued at USD 13.38 billion in 2025 and estimated to grow from USD 14.52 billion in 2026 to reach USD 21.86 billion by 2031, at a CAGR of 8.52% during the forecast period (2026-2031).

This report is Segmented by Material (Plastics, Rubbers, and Specialty Polymers), Application (Bulk Disposable Tubing, and More), Structure (Single Lumen, and More), End-User (Hospitals, and More), Manufacturing Process (Single-Screw Extrusion, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
CDC data show 76.4% of U.S. adults living with at least one chronic condition. Long-term therapies such as dialysis, cardiovascular interventions, and sustained drug infusion depend on reliable tubing able to remain in-body or in-home for extended periods. An aging population magnifies at-home treatment, prompting need for user-friendly sets with audible alarms and kink-resistant lumens. Cardiovascular disease growth boosts adoption of advanced catheter tubing designed for pulsed-field ablation and transcatheter valve replacement. Disposable lines protect immunocompromised patients by minimizing infection risk in frequent infusion scenarios.
Interventional radiology alone is projected to exceed USD 43 billion by 2029 and requires ultra-slim catheters with high torsional stability. Thermally drawn polymer fibers now permit MR-guided therapy that avoids ionizing radiation, shifting design goals toward non-ferromagnetic materials and tight tolerances. Device leaders such as Medtronic have incorporated modified diamond frames that improve access during transcatheter valve deployment. Tip geometry innovation further refines aspiration and stent delivery, all increasing demand for precision micro-extrusion.
Manufacturers must align quality systems with ISO 13485:2016 by February 2026 under the FDA's amended regulation. Updated guidance now demands exhaustive chemical characterization, pushing extractable and leachable studies into multi-month projects that lengthen R&D cycles. In Europe, MDR, REACH, and RoHS layers elevate documentation effort, especially for PVC lines containing stabilizers. The emergent crackdown on PFAS adds uncertainty for fluoropolymer users, forcing pipeline audits and potential material swaps. High user fees amplify overhead, and smaller firms without in-house regulatory teams face margin squeeze or exit decisions.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Plastics retained 38.12% share of the medical tubing market in 2025 owing to mature supply chains and competitive cost structures. Specialty polymers, however, are advancing at a 10.18% CAGR as complex cardiovascular, neurovascular, and drug delivery devices require superior lubricity, kink resistance, and bio-inertness. The sustainability debate has accelerated substitution of conventional PVC with TPEs that deliver comparable clarity and softness absent DEHP plasticizers. Ultra polyimide, PEBAX, and bio-circular PA11 are now mainstream in premium catheter assemblies. Suppliers that can scale these resins under ISO 13485-compliant conditions gain pricing power. Regulatory scrutiny surrounding PFAS is encouraging early moves toward fluorine-free alternatives in high-pressure angiographic lines.
Polymer innovation also answers recyclability mandates, with advanced depolymerization research aiming at closed-loop medical PVC recovery. Specialty elastomers command higher ASPs yet prove cost-neutral over life cycle due to fewer device failures. Material data sheets now include embodied carbon metrics that hospital sustainability officers review during tenders. As a result the medical tubing market size attributed to specialty polymers is projected to headline absolute gains through 2031.
Drug delivery systems accounted for 29.31% of 2025 revenue, underscoring the central role tubing plays in precision dosing and infusion accuracy. Chemotherapy, biologics, and long-acting injectables depend on tight inner-diameter tolerances and low extractables to maintain compound integrity. Smoke evacuation and suction lines, growing at 11.45% CAGR, reflect heightened surgeon awareness of airborne particulate hazards in operating theatres. Catheter-based cardiovascular therapy remains an anchor, yet product life cycles shorten as hospitals seek next-generation devices that cut fluoroscopy time and radiation dose.
Dialysis and extended IV therapies spur demand for kink-resistant silicone-free lines safe for overnight use. Enteral feeding sets incorporate antimicrobial layers and RFID tags to combat misconnections. Peristaltic pump demand remains stable as lab automation expands. 3D-printed, patient-matched airway stents illustrate early clinical adoption of additive tubing, hinting at wider customization potential. Together these dynamics secure drug delivery's leadership while enabling high-growth niches that elevate overall medical tubing market value.
North America retained 41.02% of 2025 revenue, propelled by high per-capita healthcare spend, a mature device manufacturing base, and a reimbursement climate that rewards advanced catheter systems. U.S. hospitals lead global adoption of sensor-ready lines that link seamlessly to electronic medical records, while Canada's universal coverage sustains steady baseline demand. The medical tubing market size in North America also benefits from concentrated R&D clusters and close industry-faculty collaboration that accelerates commercialization.
Asia-Pacific represents the fastest-growing region at 9.38% CAGR through 2031. China and India spearhead expansion due to broad population bases, chronic disease incidence, and domestic production scale-ups supported by multinational joint ventures. Lubrizol's USD 350 million investment near Chennai exemplifies inbound capital directed at regional extrusion capacity that cuts lead times for local OEMs. ASEAN's 620 million inhabitants and harmonized regulatory work-sharing further entice suppliers eager to diversify beyond legacy Western demand.
Europe maintains moderate growth driven by regulatory harmonization under MDR and a strong push for recyclable medical polymers. Germany anchors manufacturing, while Nordic innovation focuses on low-carbon materials compatible with hospital sustainability goals. The EU Packaging and Packaging Waste Regulation, which sets 2030 recyclability targets, is accelerating shift toward bio-circular resins and closed-loop designs. Overall regional progress remains steady despite Brexit-related complexity affecting United Kingdom certification pathways.